RET
RET fusions in NSCLC and thyroid cancers. Targeted by selpercatinib and pralsetinib.
No Clinical Trials found for this biomarker.
RET fusions in NSCLC and thyroid cancers. Targeted by selpercatinib and pralsetinib.
No Clinical Trials found for this biomarker.